CGON stock forecast, quote, news & analysis
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer... Show more
Why CG Oncology (CGON) Is Up +12% in the Last 30 Days
Key Takeaways
- CGON stock rose +12% over the past 30 days, driven by positive clinical trial updates and accelerated timelines for Phase 3 data readouts.
- Over the past quarter, shares gained +62%, reflecting strong momentum from ongoing bladder cancer program advancements.
- Key catalysts include expedited PIVOT-006 topline data expected in H1 2026 and durable efficacy data from BOND-003 trials.
- Analyst price target increases, such as H.C. Wainwright to $80, bolstered investor sentiment.
- Biotech sector trends and enthusiasm for bladder-sparing therapies supported the price movement.
CG Oncology (CGON) Company Overview and Market Position
CG Oncology, Inc. (CGON) is a late-stage clinical biopharmaceutical company focused on developing and commercializing cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy designed as a bladder-sparing therapeutic for patients with non-muscle invasive bladder cancer (NMIBC). The company's core business model centers on advancing this intravesical therapy through Phase 3 trials, targeting high unmet needs in BCG-unresponsive and intermediate-risk NMIBC where current treatments like BCG often fail. In the competitive biotechnology landscape, CG Oncology differentiates itself with cretostimogene's promising durability and tolerability profile, positioning it as a potential backbone therapy. These fundamentals, including robust clinical data and regulatory progress, directly underpin the recent stock price appreciation amid positive trial momentum.
CG Oncology (CGON) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, CGON stock climbed from approximately $60.55 (early March close) to $67.68, marking a +12% gain. The movement was trend-driven with moderate volatility, peaking near $69 before stabilizing around recent highs.
For the past quarter, shares surged +62% from around $41.79 (early January) to $67.68. This upward trajectory featured steady gains punctuated by news-driven spikes, outperforming broader biotech indices amid clinical optimism.
What Drove CGON Stock Price in the Last 30 Days
The 30-day uptick was propelled by continued enthusiasm from January's PIVOT-006 Phase 3 timeline acceleration to H1 2026, announced nearly a year ahead of schedule due to rapid enrollment. This news, evaluating cretostimogene in intermediate-risk NMIBC (first such randomized trial), fueled optimism for expanded market potential. H.C. Wainwright raised its price target to $80 post-year-end results, citing strong BLA submission prospects and best-in-disease profile. Positive sentiment from prior BOND-003 data, showing high complete response rates and safety, sustained buying interest. Sector tailwinds in oncology biotechs amplified the stock analysis focus on CGON's price movement.
What Drove CGON Stock Performance Over the Last Quarter
The quarterly rally built on sustained narratives around cretostimogene's Phase 3 programs. January's PIVOT-006 update triggered sharp gains, with shares rallying ~32% in a week. February's year-end financials highlighted expedited milestones, including CORE-008 combination data and BLA preparations for high-risk BCG-unresponsive NMIBC. December SUO presentation of BOND-003 Cohort P data (high-grade event-free survival up to 95.7%) reinforced efficacy. Institutional interest, despite some profit-taking, and biotech market recovery from macro pressures like interest rates drove cumulative impact, with market trends favoring oncology innovators.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the top-performing AI trading bots from its extensive library of hundreds of algorithms actively trading thousands of tickers across various markets. This curated section highlights bots with the strongest recent performance, relevance to current market conditions, and diverse strategies—ranging from short-term scalping to long-term trend following, with metrics like win rate, profit factor, and Sharpe ratio. Whether focusing on momentum, mean reversion, or volatility breakouts, these bots offer transparent backtested and live results to help investors automate trading. Explore the page to identify bots suited to your timeframe and risk tolerance, potentially enhancing your stock analysis toolkit.
CGON Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor PIVOT-006 topline data in H1 2026 for intermediate-risk NMIBC, alongside BLA submission progress for high-risk BCG-unresponsive indications. Upcoming CORE-008 results on combinations with gemcitabine and regulatory feedback will shape sentiment. Industry trends in bladder cancer treatments, macroeconomic factors like interest rates impacting biotech funding, and competitive developments in oncolytic immunotherapies remain key. Risks include trial outcomes, FDA decisions, and cash burn, while catalysts like partnerships or analyst updates could influence price movement.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
CGON's RSI Oscillator ascending out of oversold territory
The RSI Indicator for CGON moved out of oversold territory on June 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 10 similar instances when the indicator left oversold territory. In of the 10 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 22 cases where CGON's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for CGON just turned positive on June 12, 2026. Looking at past instances where CGON's MACD turned positive, the stock continued to rise in of 26 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CGON advanced for three days, in of 126 cases, the price rose further within the following month. The odds of a continued upward trend are .
CGON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on May 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CGON as a result. In of 40 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
CGON moved below its 50-day moving average on May 15, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CGON crossed bearishly below the 50-day moving average on May 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 8 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGON declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for CGON entered a downward trend on June 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CGON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.812) is normal, around the industry mean (18.720). P/E Ratio (0.000) is within average values for comparable stocks, (36.072). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.682). CGON has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (909.091) is also within normal values, averaging (357.550).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology